BIOMAT Database Logo BIOMAT Database Logo

Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin. 1990

Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.

Changes in thyroid volume during antithyroid drug therapy for Graves' disease compared with circulating thyroid parameters were evaluated. One hundred and forty-four patients with Graves' disease were treated with methimazole. Thyroid volume was measured by ultrasonography (thyroid volume = pi abc/6, where a is length, b width, and c depth). Serum TSH, TSH-binding inhibitory immunoglobulins, thyroid-stimulating antibodies, thyroglobulin, antimicrosomal antibodies, and antithyroglobulin antibodies were also measured. In the whole group of patients, thyroid volume correlated significantly with thyroglobulin (p less than 0.01) and TSH-binding inhibitory immunoglobulins (p less than 0.01), but not with TSH, antimicrosomal antibodies, and antithyroglobulin antibodies. Furthermore, a positive correlation was found between thyroglobulin and TSH-binding inhibitory immunoglobulins (p less than 0.01). In 11 patients the mean thyroid volume decreased significantly after one year of therapy (p less than 0.01), associated with decreasing levels of serum TSH-binding inhibitory immunoglobulins. Ten patients experienced transient hypothyroidism with an overdose of methimazole, and the mean thyroid volume increased significantly (p less than 0.01) with increasing serum TSH levels. In conclusion, it is suggested that TSH receptor antibodies may have a thyroid growth-stimulating effect. In addition, circulating thyroglobulin levels reflect thyroid volume in Graves' disease.

UI MeSH Term Description Entries
D008297 Male Males
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
September 2019, Endocrinology and metabolism (Seoul, Korea),
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Changes in serum autoantibodies to thyroid peroxidase during antithyroid drug therapy for Graves' disease.
April 1990, Endocrinologia japonica,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Triiodothyronine autoantibodies in Graves' disease: their changes after antithyroid therapy and relationship with the thyroglobulin antibodies.
January 1990, Acta endocrinologica,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.
April 2003, Clinical endocrinology,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
The prognostic value of TSH receptor binding and thyroid stimulating antibodies following antithyroid drug treatment of Graves' disease.
November 1989, Acta endocrinologica,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse.
December 1991, Journal of the Formosan Medical Association = Taiwan yi zhi,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
August 1990, The American journal of medicine,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Thyroid antibodies and thyroglobulin-like products in serum during antithyroid therapy.
November 1970, Acta medica Scandinavica,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
March 1983, The Journal of clinical endocrinology and metabolism,
Y Yamaguchi, and T Inukai, and A Iwashita, and M Nishino, and T Yamaguchi, and Y Shohda, and Y Shimomura, and K Ohshima, and S Kobayashi, and I Kobayashi
Characteristics of anti-TSH receptor antibodies in two patients who developed spontaneous hypothyroidism after antithyroid drug therapy for hyperthyroid Graves' disease.
July 1987, The Tohoku journal of experimental medicine,
Copied contents to your clipboard!